These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2772869)

  • 1. Shortened method for the determination of euglobulin lysis time employing Malayan pit viper venom.
    Starr T; Gertler MM
    Thromb Res; 1989 Jun; 54(5):511-7. PubMed ID: 2772869
    [No Abstract]   [Full Text] [Related]  

  • 2. Fibrinolysis in the pigeon (Columba livia).
    Ahmad N; Dube B; Agarwal GP; Dube R
    Thromb Haemost; 1979 Oct; 42(3):955-8. PubMed ID: 505408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of coagulation on the activation of plasminogen by streptokinase and urokinase.
    Takada A; Urano T; Takada Y
    Thromb Haemost; 1979 Oct; 42(3):901-8. PubMed ID: 505405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of five streptokinase formulations using the euglobulin lysis test and the plasminogen activation assay.
    Couto LT; Donato JL; de Nucci G
    Braz J Med Biol Res; 2004 Dec; 37(12):1889-94. PubMed ID: 15558196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of urokinase upon euglobulin lysis time and thrombin time.
    Lee TK; Huang SC; Lin SA; Chien LM
    Taiwan Yi Xue Hui Za Zhi; 1976 Mar; 75(03):190-7. PubMed ID: 1066436
    [No Abstract]   [Full Text] [Related]  

  • 6. THE EUGLOBULIN METHOD FOR ESTIMATION OF FIBRINOLYTIC ACTIVITY IN UROKINASE-ACTIVATED PLASMA, AND THE INFLUENCE OF TRASYLOL.
    BLIX S
    Scand J Clin Lab Invest; 1964; 16():198-200. PubMed ID: 14161857
    [No Abstract]   [Full Text] [Related]  

  • 7. Ancrod enhances the thrombolytic effect of streptokinase and urokinase.
    Cercek B; Lew AS; Hod H; Yano J; Lewis B; Reddy KN; Ganz W
    Thromb Res; 1987 Aug; 47(4):417-26. PubMed ID: 3660351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained fibrinolytic activity in the euglobulin fraction induced by concomitant administration of urokinase and dextran sulphate.
    Matsuo O; Kawaguchi T; Kosugi T; Mihara H
    Thromb Res; 1978 Dec; 13(6):1125-30. PubMed ID: 749265
    [No Abstract]   [Full Text] [Related]  

  • 9. Factor XIII cross-linking and the rate of fibrinolysis induced by streptokinase and urokinase.
    Rampling MW
    Thromb Res; 1978 Feb; 12(2):287-95. PubMed ID: 635844
    [No Abstract]   [Full Text] [Related]  

  • 10. Blood fibrinolytic system in rana tigrina.
    Srivastava VM; Dube B; Dube RK; Agarwal GP; Ahmad N
    Thromb Haemost; 1981 Jun; 45(3):252-4. PubMed ID: 7281104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different effect of 5,6-trans-prostaglandin E2 on plasminogen activation by urokinase and streptokinase.
    Urano T; Ikeda C; Shimokawa M; Kinoshita T
    Biochim Biophys Acta; 1994 Apr; 1205(2):258-61. PubMed ID: 8155706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impairment of fibrinolysis by streptokinase, urokinase and recombinant tissue-type plasminogen activator in the presence of radiographic contrast agents.
    Dehmer GJ; Gresalfi N; Daly D; Oberhardt B; Tate DA
    J Am Coll Cardiol; 1995 Apr; 25(5):1069-75. PubMed ID: 7897118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen-fibrin related antigen pattern in human blood. Incomplete lysis of whole blood clots by urokinase.
    Jacobsen CD; Fry GL; Wu KK; Southers NJ
    Thromb Res; 1975 Apr; 6(4):327-36. PubMed ID: 1079637
    [No Abstract]   [Full Text] [Related]  

  • 14. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro.
    Tanaka A; Suzuki Y; Sugihara K; Kanayama N; Urano T
    Life Sci; 2009 Jul; 85(5-6):220-5. PubMed ID: 19500599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses.
    Summaria L; Sandesara J; Yang G; Vagher JP; Caprini JA
    Thromb Haemost; 1986 Aug; 56(1):71-9. PubMed ID: 2946093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interaction of C1-esterase inhibitor and plasmin in human euglobulin.
    Highsmith RF; Burnett CJ; Weirich CJ
    J Lab Clin Med; 1979 Mar; 93(3):459-71. PubMed ID: 155127
    [No Abstract]   [Full Text] [Related]  

  • 17. Dissolution of thrombi by tissue plasminogen activator, urokinase and streptokinase in an artificial circulating system.
    Mattsson C; Nyberg-Arrhenius V; Wallén P
    Thromb Res; 1981 Mar; 21(6):535-45. PubMed ID: 7022741
    [No Abstract]   [Full Text] [Related]  

  • 18. Proceedings: Fibrinolysis versus fibrinogenolysis: the specificity of human vascular activator (VA) as compared to urokinase (UK) and streptokinase (SK).
    Lipinski B; Gurewich V; Hyde E
    Thromb Diath Haemorrh; 1975 Sep; 34(1):351. PubMed ID: 1188799
    [No Abstract]   [Full Text] [Related]  

  • 19. Coronary thrombolysis: pharmacological considerations with emphasis on tissue-type plasminogen activator (t-PA).
    Fox KA; Bergmann SR; Sobel BE
    Biochem Pharmacol; 1984 Jun; 33(12):1831-8. PubMed ID: 6233982
    [No Abstract]   [Full Text] [Related]  

  • 20. Euglobulin lysis times: an update.
    Glassman A; Abram M; Baxter G; Swett A
    Ann Clin Lab Sci; 1993; 23(5):329-32. PubMed ID: 8239479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.